Relmada Therapeutics/$RLMD
1D1W1MYTD1Y5YMAX
Capital at risk
About Relmada Therapeutics
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
- Ticker
- $RLMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17
- Headquarters
- Coral Gables, United States
- Website
- www.relmada.com
RLMD Metrics
BasicAdvanced
$403M
-
-$0.85
0.49
-
Price and volume
Market cap
$403M
Beta
0.49
52-week high
$8.00
52-week low
$1.53
Average daily volume
1.1M
Financial strength
Current ratio
29.517
Quick ratio
29.342
Profitability
Management effectiveness
Return on assets (TTM)
-32.39%
Return on equity (TTM)
-55.66%
Valuation
Price to book
1.95
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-6.019
Free cash flow yield (TTM)
-16.61%
Free cash flow per share (TTM)
-0.628
Growth
Earnings per share change (TTM)
-61.36%
3-year earnings per share growth (CAGR)
-41.81%
What the Analysts think about RLMD
Analyst ratings (Buy, Hold, Sell) for Relmada Therapeutics stock.
Analyst projections of the future price of Relmada Therapeutics stock.
Bulls say / Bears say
NDV-01 produced strong Phase 2 results, with a 95% complete response rate at any time and a 76% response rate maintained at 12 months in high-risk NMIBC. The BCG-unresponsive subgroup recorded an 80% 12-month response rate, with no serious treatment-related adverse events reported. (Relmada Therapeutics)
Relmada says it has written FDA alignment on two registrational pathways for NDV-01, including the study designs and primary endpoints. Clinical sites are engaged and prepared to enrol once the IND is cleared, giving the programme a defined route towards pivotal testing. (GlobeNewswire)
The company ended June with $217.7 million in cash, cash equivalents and short-term investments, and management expects this to fund operations through 2029, including the NDV-01 Phase 3 programme. That reduces near-term financing pressure while the lead asset advances. (GlobeNewswire, The Motley Fool)
The NDV-01 IND target has slipped from mid-2026 to year-end because manufacturing scale-up and GMP scheduling remain the main bottlenecks. That delays the Phase 3 start and leaves room for further timetable slippage. (Yahoo Finance, GlobeNewswire)
The encouraging NDV-01 results come from an open-label, single-arm, single-centre Phase 2 study. Without a randomised comparator, the response rates may not translate into the same benefit in Phase 3. (GlobeNewswire)
Sepranolone is still an unproven asset: Relmada plans only to file an IND and start a Phase 2 proof-of-concept study in Prader-Willi syndrome. It therefore offers optionality, but no demonstrated clinical benefit yet. (Seeking Alpha, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
RLMD Financial Performance
Revenues and expenses
RLMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
RLMD News
AllArticlesVideos
Funds containing RLMD
Fund name | Fund size | $RLMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.